On 23rd, the news that "the price of some pharmacies rose by more than 5% after the' out-of-stock' of Lianhua Qingwen" appeared on the hot search.
Some media reported that some pharmacies raised the price of Lianhua Qingwen Capsule to varying degrees. Among them, the price increase of .35g*48 capsules/box is obvious. There is a pharmacy located in Heyuan City, Guangdong Province. At present, the price of Lianhua Qingwen Capsule with the specification of .35g*48 capsules/box is 46 yuan/box. Based on the previous general selling price of about 3 yuan/box, the price has been increased by over 5%.
As for the reason for the price increase, the report said that some pharmacy staff said, "Lianhua Qingwen has recently increased its price, and there have been a lot of people buying it recently. The manufacturer's pricing has gone up, and the goods can't be ordered. It must be adjusted in price. " Some pharmacy employees also said, "The purchase price is expensive."
So, did Yiling Pharmaceutical, the manufacturer of Lianhua Qingwen, raise the price of related drugs? Is it universal for pharmacies to raise prices sharply and sell even flowers to clear the plague?
In this regard, the relevant person in charge of Yiling Pharmaceutical responded to the reporter of Securities Times E Company on the 23rd, saying that "the company did not raise the price of drugs related to Lianhua Qingwen".
the reporter of company e also contacted a head listed company of instant digital pharmacy, which has established 351 smart pharmacy networks in 17 cities across the country. The relevant person in charge of the company told the reporter that the price of anti-epidemic drugs such as Lianhua Qingyi on the platform has not changed. At present, we have not heard the news of price increase by manufacturers. The fluctuation of drug prices in various pharmacies may be due to different promotions at different times. "In terms of supply, on the whole, the supply of drugs such as Lianhua Qingwen on our platform can be guaranteed, and no out-of-stock phenomenon has been found. Sometimes we can't place an order at night because of replenishment in the background, and we will also increase procurement and supply. "
Yiling Pharmaceutical issued a statement
Recently, it was rumored in the market that Lianhua Qingwen Capsule and Lianhua Qingwen Granule were out of stock in some areas, which was also a big background for the hot search that "the price of some pharmacies rose by over 5%".
in response to the rumor that the goods are out of stock, the relevant person in charge of Yiling Pharmaceutical said in response to the reporter of E Company that Yiling Pharmaceutical has been doing a series of work to improve its production capacity in the past two years, and its production capacity has been greatly improved at present. The factories producing Lianhua Qingwen products include Shijiazhuang, Beijing, Hengshui and other places, and the current production has basically not been affected. It also said that the production plan of Yiling Pharmaceutical is "fixed production by sales", and the production plan can be adjusted in time according to market demand to ensure the supply of the market. At present, sales are all normal.
it is worth mentioning that under the background of "out of stock" in some areas such as Lianhua Qingwen, a number of counterfeit "Lianhua" series products have appeared in the market recently. In this regard, on November 22nd, Yiling Pharmaceutical issued a statement saying that there have been many commodities named Lianhua Qingwen Tea, Lianhua Qingwen Tea, Lianhua Qingwen Ointment, Lianhua Qingwen Plant Beverage and Lianhua Qingwen Pill in the market recently, and these products are not products produced, sold or authorized by Yiling Pharmaceutical. Yiling Pharmaceutical said that the above-mentioned products are similar or similar to the brand name and packaging of "Yiling Lianhua Qingwen" (medicine) produced by the company and Lianhua brand "Lianhua Qingfei Tea" (beverage) produced by its subsidiaries, which is easily confused, and consumers have made great misunderstandings about this. Yiling Pharmaceutical also mentioned that "Lianhua Qingwen", "Lianhua Qingwen" and "Lianhua Qingfei" are trademarks registered by the company according to law and obtained the exclusive right to use trademarks, but the design patent of "Lianhua Qingwen Capsule" produced by it is not authorized to be used by others. The company reserves the right to investigate the legal responsibilities of the responsible person for producing and selling counterfeit products, confusing the company's products and other acts that infringe the legitimate rights and interests of the company's exclusive right to use trademarks.
The stock price has soared recently
The main business of Yiling Pharmaceutical Co., Ltd. is the research and development, production and sales of patented innovative Chinese medicines. The series of Lianhua Qingwen products produced and sold by Yiling Pharmaceutical Co., Ltd. have attracted attention because they have entered the COVID-19 diagnosis and treatment program many times.
It is worth mentioning that, as a producer of Lianhua Qingwen, Yiling Pharmaceutical has been continuously sought after by funds in the secondary market recently.
Market data shows that the share price of Yiling Pharmaceutical has been rising from about 18.8 yuan in less than two months since the end of September. Especially since November, with the enlargement of trading volume, Yiling Pharmaceutical has issued two announcements of changes due to the continuous rise of its share price, and hit a record high of 48.66 yuan/share on November 21st. However, the stock price has been adjusted back in the past two trading days, and the latest closing price is 39.99 yuan.
In terms of operating performance, in the first three quarters of this year, Yiling Pharmaceutical achieved a total operating income of 7.946 billion yuan, down 2.4% year-on-year; The net profit returned to the mother was 1.414 billion yuan, up 15.58% year-on-year, and the non-net profit was 1.416 billion yuan, up 2.6% year-on-year; In Q3, the total operating income was 2.38 billion yuan, up 7.41% year-on-year. The net profit returned to the mother was 366 million yuan, up 4.92% year-on-year, and the non-net profit was 365 million yuan, up 49.32% year-on-year.
In terms of products, the sales of Lianhua Qingwen and other drugs produced by Yiling Pharmaceutical have increased significantly this year. According to the announcement, in the first three quarters, the income of Tongshenqi, the main product of Yiling Pharmaceutical, was slightly lower than that of the same period in 221 due to various factors such as the epidemic situation. However, since Q3, cardiovascular and cerebrovascular products have gradually recovered, and the single-season cardiovascular and cerebrovascular products in Q3 have achieved a slight increase year-on-year; Lianhua Qingwen is a special product for treating COVID-19, influenza and cold, and its income will still increase year-on-year in 221 at a high base.
After the release of the third quarterly report, Yiling Pharmaceutical also attracted many institutional investors. Talking about the overseas export of Lianhua Qingwen, the company said that at present, Lianhua Qingwen has been registered and approved for listing in more than 2 countries and regions. This year, Lianhua Qingwen has continued its good sales trend last year. In the future, the company will continue to promote the overseas registration and sales of Lianhua Qingwen.